Connect with us

Technology

NeoImmuneTech’s New Data at ASCO 2024 Highlights Enhanced Benefits of Combining NT-I7 with Checkpoint Inhibitors (CPI) in Immuno-Oncology

Published

on

Results from study NIT-110 with NT-I7 and CPI combination treatment show median overall survival (mOS) improvements over standard of care treatment in pancreatic cancer and MSS colorectal cancerCorrelative analysis identified potentially predictive protein biomarkers associated with patients experiencing the most clinical benefits from combination treatment of NT-I7 and CPICombination of NT-I7 and oncolytic virus demonstrates clear survival improvement in preclinical glioblastoma results

ROCKVILLE, Md., June 3, 2024 /PRNewswire/ — NeoImmuneTech, Inc. (NIT), a T cell-focused therapeutics company, today announced promising interim results of its major clinical trial NIT-110 of NT-I7 (efineptakin alfa), at the 2024 American Society of Clinical Oncology (ASCO) global meeting held in Chicago, from May 31 to June 4. The company also presented two additional posters at the conference.

NIT-110 is a foundational clinical trial for NT-I7 that aims to confirm the safety and efficacy of combining NT-I7 with pembrolizumab (Keytruda®) in solid tumors. The data presented at ASCO 2024 confirmed that the combination is safe and well-tolerated.

Key findings from NIT-110 include:

Pancreatic cancer – Data showed a median overall survival (mOS) of 11.1 months among the 48 pancreatic cancer patients included in the study. The mOS for pancreatic cancer patients who have received a second-line standard of care treatment is currently known to be 6.1 months[1]. This mOS improvement is particularly noteworthy considering that 93.75% of the patients are receiving the combination treatment as third-line or beyond.MSS colorectal cancer -The mOS for the 50 microsatellite-stable (MSS) colorectal cancer patients was 13.2 months. The mOS for the current standard of care treatment is 10.8 months[2].

These results underscore the improved efficacy of the NT-I7 and Keytruda combination over existing standard of care treatments.

A separate poster from trial NIT-110 revealed a correlative analysis identifying a potentially predictive biomarker. These biomarkers may help identify patient populations more likely to benefit clinically from the NT-I7 and Keytruda combination. NeoImmuneTech is committed to further biomarker validation to enhance clinical outcomes.

Additionally, a preclinical study presented at ASCO 2024 highlighted the combination of NT-I7 with an oncolytic virus (ZIKV) in a glioblastoma animal model. Results demonstrated a significant increase in tumor specific CD8 T cells in the tumor microenvironment, leading to improved survival rates. Furthermore, 80% of cases in the experimental group combining NT-I7 with immune checkpoint inhibitors resulted in complete tumor eradication. NT-I7 continues to show clinical benefits driven by T cell amplification when combined with immune therapies.

NeoImmuneTech’s CEO, Luke Oh, PhD, said: “We are very encouraged by the improved clinical efficacy over standard of care in pancreatic and colorectal cancer, a notoriously difficult to treat cancer. These findings confirm our promising preclinical data and open new pathways to further enhance clinical outcomes. We are actively discussing the next steps with Merck. The results presented at ASCO 2024 confirm our strategy to continue to develop NT-I7 in the larger and high-potential immuno-oncology market.”

Posters references:

Abstract #

Track

Poster board #

Title

2621 (Link)

Developmental Therapeutics -Immunotherapy

100

A Phase 2a study of NT-I7 (efineptakin alfa), a long-acting IL-7, and pembrolizumab to evaluate efficacy, including overall survival, in hard-to-treat MSS-CRC and PDAC gastrointestinal tumors

2563

(Link)

Developmental Therapeutics -Immunotherapy

42

Investigation of a potential protein biomarker signature that may predict clinical benefit of NT-I7 and pembrolizumab in patients with cold gastrointestinal tumors

2043

(Link)

Central Nervous System Tumors

342

Expand and pull: a new treatment paradigm for glioblastoma using a long-acting recombinant interleukin-7 and oncolytic viral therapy

 

About Study NIT-110
NIT-110 is an open label Phase 2a clinical trial supported by Merck that aims to confirm the efficacy of combining NT-I7 with Keytruda in two solid tumors. Early results in 2022 had confirmed the efficacy of the combination in pancreatic cancer and MSS colorectal cancer patients, who are known to be unresponsive to immune checkpoint inhibitors alone. Consequently, 24 and 25 additional patients were recruited for each group, respectively, bringing the total to 48 pancreatic cancer patients and 50 MSS colorectal cancer patients currently undergoing clinical trials. Results presented at ASCO 2024 provide an updated analysis including the original and expansion cohorts.

About NT-I7 (efineptakin alfa) (rhIL-7-hyFc)

NT-I7 (efineptakin alfa) is the only clinical-stage long-acting human IL-7, and is being developed in oncologic and immunologic indications, where T cell amplification and increased functionality may provide clinical benefit. IL-7 is a fundamental cytokine for naïve and memory T cell development and for sustaining immune response to chronic antigens (as in cancer) or foreign antigens (as in infectious diseases). NT-I7 exhibits favorable PK/PD and safety profiles, making it an ideal combination partner. NT-I7 is being studied in multiple clinical trials in solid tumors and as vaccine adjuvant. Studies are being planned for testing in hematologic malignancies, additional solid tumors and other immunology-focused indications.

About NeoImmuneTech, Inc.
NeoImmuneTech, Inc. (NIT) is a clinical-stage T cell-focused biopharmaceutical company dedicated to expanding the horizon of immuno-oncology and enhancing immunity to infectious diseases. NIT is led by the scientific founder and inventor of NT-I7 (efineptakin alfa) and has a strong executive team with rich industry experience. NIT is expanding rapidly in personnel and operations, as well as partnering with industry and academic leaders to investigate NT-I7 as monotherapy and in combination with various immunotherapeutics. For more information, please visit www.neoimmunetech.com.

Forward-looking Statements

The statements contained herein may contain certain forward-looking statements relating to NeoImmuneTech, Inc. (the “Company”) that are based on its beliefs and expectations about the future. These forward-looking statements are based on a number of assumptions about the future, some of which are beyond the Company’s control and are not a guarantee of future performance or developments. Such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company does not undertake any obligation to update any forward-looking statements to reflect events that occur or circumstances that arise after the date of these documents. Accordingly, you should not place reliance on any forward-looking information or statements contained herein.

Some of the data contained in these documents were obtained from various external sources, and the Company has not independently verified such data. Accordingly, the Company makes no representations as to the accuracy or completeness of the data, and such data involves risks and uncertainties and is subject to change based on various factors.

[1] Wang-Gillam et al. Lancet. 2016. doi:10.1016/S0140-6736(15)00986-1
[2] Prager et al. N Engl J Med. 2023. doi:10.1056/NEJMoa221496

 

View original content:https://www.prnewswire.com/news-releases/neoimmunetechs-new-data-at-asco-2024-highlights-enhanced-benefits-of-combining-nt-i7-with-checkpoint-inhibitors-cpi-in-immuno-oncology-302161746.html

SOURCE The NeoImmuneTech, Inc

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

We Mean Business Coalition: New polling shows overwhelming global business support for clean electrification amid fossil fuel volatility

Published

on

By

LONDON, June 15, 2026 /PRNewswire/ — A landmark global survey of business executives across 18 countries shows overwhelming support for a rapid transition to electrified economies run predominantly on renewables-based electricity.

The findings suggest geopolitical instability is accelerating an existing business shift toward clean electrification, but that power systems, grids and policy frameworks are not keeping pace.

As geopolitical tensions continue in the Middle East, and G7 leaders gather in Evian amid growing concern over economic resilience and global vulnerabilities, 91% of business leaders say electrification would improve energy security, and 79% say instability has made their own business shift to electrification more urgent.

Collected during late April as the Strait of Hormuz remained closed, the data indicates business executives across all polled countries support a rapid move away from fossil fuel systems, with 90% expecting their operations to be electrified by 2035.

The polling comes after an International Energy Agency (IEA) report found repeated energy shocks are reshaping government and company investment priorities, while the Turkish and Australian COP31 hosts and the International Renewables Agency (IRENA) have called for a stronger global push to run vehicles, industry and buildings on electricity rather than fossil fuels.

The data shows that 90% of business leaders surveyed say transitioning to a renewables-based electricity system in their country is likely to boost economic growth and 88% say electrifying their operations will make their business more competitive.

However, 72% of those surveyed say government policies are lagging behind.

Powering Up: Business Perspectives on Electrification warns that countries failing to electrify risk losing out to more electrified economies, with 62% saying they would consider moving operations if their government did not offer sufficient support to electrify.

The polling, conducted across key economies and emerging markets, was commissioned by E3G, We Mean Business Coalition and the Global Renewables Alliance, and underscores growing business demand for clean electrification as a strategy for energy security, competitiveness and economic growth, as well as tackling climate change.

Business leaders of medium-sized and large organisations were surveyed in Australia, Brazil, China, Colombia, France, Germany, India, Indonesia, Japan, Kenya, Nigeria, Philippines, Poland, South Africa, South Korea, Turkey, United Kingdom and United States.

Find the full press release and report here.

View original content:https://www.prnewswire.com/news-releases/we-mean-business-coalition-new-polling-shows-overwhelming-global-business-support-for-clean-electrification-amid-fossil-fuel-volatility-302795473.html

SOURCE We Mean Business Coalition

Continue Reading

Technology

AI reshapes global labour market into two distinct paths, rewarding human skills: PwC 2026 Global AI Jobs Barometer

Published

on

By

AI is creating a ‘two-track’ labour market: ‘professionalised’ roles (in which AI acts like a force multiplier for experts, requiring more human-intensive skills) see greater growth across headcount and wages than ‘democratised’ roles (in which AI makes the role itself easier for non-experts to perform)Companies most able to use AI are seeing faster headcount growth than the least AI-exposed companies (52% vs 36%) and higher wage growth (24% vs 17%)”Super-star companies” most exposed to AI achieved labour productivity gains of 163%, significantly outpacing other businessesJobs requiring specific AI skills are growing almost eight times (69%) faster than the total jobs market (9%), with the average wage premium for AI skills rising to 62%Entry-level outlook diverges: Analysis of US data shows AI-exposed entry-level roles are seven times more likely to require traditionally senior-level skills such as judgement and leadership. These roles grew 35% since 2019, while other entry-level roles declined by 10%

LONDON, 15 June 2026 /CNW/ — AI is rapidly reshaping the skills employers want most from workers – increasing the emphasis on human skills such as judgement, creativity and leadership – as companies most able to use AI continue to expand hiring faster than their peers, according to PwC’s 2026 Global AI Jobs Barometer, released today. 

The Barometer, which analysed more than one billion job ads across six continents, also finds that AI is driving a ‘two-track’ global labour market in which ‘professionalised’ roles – in which AI automates routine tasks so human judgement and expertise are emphasized – are growing faster than roles ‘democratised’ by AI – in which AI makes the role itself easier for non-experts to perform.

‘Professionalised’ roles (such as radiologists or recruiters) are seeing twice the growth in available jobs and 42% faster salary growth than those categorised as ‘democratised’ (such as IT service managers or medical secretaries).

At the entry level, AI appears to be increasing demand for more ‘senior’ skills from junior workers. Based on 2.4 million entry-level jobs analysed in the US, entry-level roles most exposed to AI are now seven times more likely to require traditionally senior-level ‘human-intensive’ skills like leadership, creativity or face-to-face interactions.

Job openings for these ‘seniorised’ entry-level roles have grown 35% since 2019, while other entry-level roles shrank 10%.

Joe Atkinson, Global Chief AI Officer, PwC, said:

“Across the global economy, we’re beginning to see a new divide emerge between different models for talent and value creation. The companies seeing the greatest returns on AI are using it to amplify human expertise, accelerate innovation and create entirely new sources of value. As a result, they are pulling further ahead on productivity and growth than companies that focus primarily on automation.”

AI is driving a productivity boom – and “super-star” companies most able to use AI are pulling ahead significantly

The report finds widening divergence between companies most and least exposed to AI. Companies operating in the most AI-exposed sectors recorded 34% productivity growth in 2025 relative to 2018, compared to 24% for the companies least able to use AI.

Within this group, a pronounced “super-star” effect is emerging. The top 20% of the most AI-exposed companies achieved average labour productivity growth of 163% relative to 2018 – nearly five times higher than the most AI-exposed companies overall.

Perhaps most surprisingly, headcount growth at the most AI-exposed companies is outpacing growth at the least AI-exposed companies – 52% relative to 36% in 2025, based on 2018 baseline levels.

Average wage premium for AI skills hits 62% as AI job postings eclipse broader labour market growth

As companies continue to boost productivity with AI, the average wage premium for workers with AI skills continued to surge higher – hitting 62%, up from 57% last year.

The wage premium varies by industry: as high as 118% in some sectors, such as consumer markets, and 16% in government and public sector work.

Jobs requiring specific AI skills – such as prompt engineering or machine learning – have also soared, growing roughly eight times (69%) as fast as the overall jobs market, at 9%. The number of AI jobs is almost twice as high as 2024, with growth in AI jobs outpacing all jobs since 2015. 

Sectors including technology, media and telecommunications (11%) and professional services (6%) sectors saw the highest share in AI job growth – with health at the lowest end (less than 1%)

Pete Brown, Global Workforce Leader, PwC, said:

“The traditional relationship between experience and expertise is changing. AI is removing some of the routine work that once acted as an apprenticeship, while increasing demand for judgement, leadership and adaptability much earlier in careers. Organisations need to rethink how they develop talent if they want people to thrive in this new environment.”

Notes to Editors

About PwC 2026 Global AI Jobs Barometer 

PwC’s 2026 AI Jobs Barometer analysed more than one billion jobs advertisements in 27 countries and territories. The Barometer combines large-scale labour market, company financial and occupational task data to understand how AI is reshaping jobs, skills, wages and productivity across the global economy. Additionally, this year’s Barometer includes targeted analysis of entry-level roles, including how the skill requirements of early-career jobs are changing in highly AI-exposed occupations. You can read the full report and learn more about the methodology and key takeaways at www.pwc.com.

About PwC 

At PwC, we help clients build trust and reinvent so they can turn complexity into competitive advantage. We’re a tech-forward, people-empowered network with more than 364,000 people in 136 countries and 137 territories. Across audit and assurance, tax and legal, deals and consulting, we help clients build, accelerate, and sustain momentum. Find out more at www.pwc.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/ai-reshapes-global-labour-market-into-two-distinct-paths-rewarding-human-skills-pwc-2026-global-ai-jobs-barometer-302798987.html

SOURCE PwC

Continue Reading

Technology

Shield AI and Destinus demonstrate autonomous strike and teaming capabilities on an interceptor system in full-mission flight exercise

Published

on

By

PARIS, June 15, 2026 /PRNewswire/ — Shield AI and Destinus have successfully demonstrated autonomous collaborative strike capabilities on the Destinus Hornet, an interceptor system designed for counter-UAS missions against loitering munitions, drone swarms, and hostile uncrewed threats at scale. The tests, conducted in Segovia, Spain, validated Shield AI’s Hivemind AI piloting abilities to support autonomy-enabled coordination and in-flight adaptation in contested airspace and demonstrated how this capability can help operators respond more quickly to large-scale unmanned threats.

The milestone builds on two prior phases of integration: Phase 1 established Hivemind platform control on the Hornet in under two months and Phase 2 demonstrated V-BAT and Hornet multi-platform teaming in flight. For this phase, the Segovia campaign executed a complete operational concept developed for the Destinus Ruta, a low-cost turbojet strike platform designed for terrain-following penetration in GNSS-denied and contested environments. Hornet served as the initial integration baseline across the Destinus family due to a shared flight control architecture. This is intended to accelerate Hivemind integration across additional Destinus systems and reduce the technical risk ahead of the planned transition to Ruta.

“Autonomous systems must be able to sense threats, adapt, and act at the edge — especially in contested environments where direct command and control is degraded or denied,” said Christian Gutierrez, senior vice president of Hivemind at Shield AI. “What we demonstrated in Segovia is a repeatable, fieldable autonomous capability that closes the reconnaissance-to-strike loop at the speed the threat demands.”

Phase 3 exercised the full mission sequence aligned to the Ruta operational concept, including autonomy-assisted mission planning via ground control station, radio testing, autonomous terrain following, in-flight target updates, and autonomous terminal maneuver execution on operator command. The next phase will transition these capabilities to the Destinus Ruta platform in Ukraine, enabling coordinated strike behaviors between V-BAT and multiple Ruta systems. This follow-on evaluation will focus on repeatability, reliability, and integration with existing operator command-and-control architectures.

“Destinus platforms operate on our own flight control architecture, and Hivemind validated that we can integrate third-party autonomy without surrendering system design authority,” said Tim Moser, chief technology officer at Destinus. “Repeatable integration, clear command authority, fieldable capability — that is how autonomy moves from a demonstration to something operators can rely on in the field.”

The Destinus Hornet is a multi-role autonomous platform capable of counter-UAS, strike, reconnaissance, data relay, and security operations. Hornet systems form part of a broader layered air-defense architecture designed to protect high-value sites and critical infrastructure.

The Hivemind AI pilot enables platforms to sense, decide, and act independently, within operator-defined parameters under established command authority. Unlike traditional autopilots that cannot deviate from preplanned routes, Hivemind dynamically reroutes mission plans, responds to unexpected conditions, avoids obstacles, and executes complex tasks safely and effectively.

Shield AI will be exhibiting at Eurosatory in Hall 5A, stand A276, and Destinus will also be exhibiting in Hall 4, stand E255.

About Shield AI:

Founded in 2015, Shield AI is a venture-backed defense-tech company with the mission of protecting service members and civilians with intelligent systems. Its products include Hivemind autonomy software and V-BAT and X-BAT aircraft. With offices and facilities across the U.S., Europe, the Middle East, and Asia-Pacific, Shield AI’s technology actively supports operations worldwide. For more information, visit www.shield.ai. Follow Shield AI on LinkedInXInstagram, and YouTube.

Media contact:

Charles Forrester, Communications Manager (Europe): media@shield.ai

About Destinus:

Destinus is a European defence and aerospace company built for the age of mass-produced threats. The company designs and manufactures autonomous strike systems and air defence systems in Europe for European and allied armed forces. Its edge is the combination of a unified autonomy stack, deep vertical integration, and industrial-scale production that turns fast iteration into fielded capability.

Media contact:

FTI Consulting: destinus@fticonsulting.com 

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/shield-ai-and-destinus-demonstrate-autonomous-strike-and-teaming-capabilities-on-an-interceptor-system-in-full-mission-flight-exercise-302799762.html

Continue Reading

Trending